PMA device
SELUTION SLR 014 PTCA Drug-Eluting Balloon
MedAlliance, LLC · Drug-Eluting Percutaneous Transluminal Coronary Angioplasty Catheter (OOB, Class III) · First FDA decision Sep 18, 2026, newest Sep 18, 2026Coronary artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
3
Naming "SELUTION SLR 014"
MAUDE reports
0
Brand "SELUTION SLR 014", since 2015
PubMed studies
0
Mentioning "SELUTION SLR 014"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SELUTION SLR 014 PTCA Drug-Eluting Balloon
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P250041 · Decided Sep 18, 2026 · 324 days after receipt
Device type: Drug-eluting percutaneous transluminal coronary angioplasty catheter (OOB) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) and Stenting of the Renal ArteriesNational analysisReview closedCAG-00085R4Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
- Percutaneous Transluminal Angioplasty (PTA)National determinationOn the books20.7Updated May 14, 2025
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "SELUTION SLR 014", any status and sponsor, newest update first.
- SELUTION SLR™ 014 In-stent RestenosisPivotal-lookingActive, not recruiting
M.A. Med Alliance S.A.Not on our public-company list
NCT04280029 · 418 participants · Start Jul 6, 2020 · Primary completion Aug 15, 2025
Device: SELUTION SLR 014 DEB; Standard of Care · For: Coronary Restenosis
Sites: Loma Linda, California; Los Angeles, California; Torrance, California · 48 sites in all
- SELUTION 4 De Novo Small Vessel IDE TrialPivotal-lookingActive, not recruiting
M.A. Med Alliance S.A.Not on our public-company list
NCT05946629 · 960 participants (planned) · Start Oct 20, 2023 · Primary completion Sep 2027
Device: PCI with SELUTION SLR DCB; PCI with FDA approved "-limus" DES · For: Coronary Artery Disease
Sites: Jonesboro, Arkansas; Chula Vista, California; Los Angeles, California · 70 sites in all
- SELUTION4BTK TrialPivotal-lookingRecruiting
M.A. Med Alliance S.A.Not on our public-company list
NCT05055297 · 376 participants (planned) · Start May 19, 2022 · Primary completion Jun 1, 2027
Device: SELUTION SLR™ DEB 014; Plain (Uncoated) Balloon Angioplasty (PTA) · For: Peripheral Arterial Disease; Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Sites: Chandler, Arizona; Jonesboro, Arkansas; Little Rock, Arkansas · 48 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SELUTION SLR 014", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OOB
673 reports: 388 malfunction, 208 injury, 76 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SELUTION SLR 014"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OOB.
- AGENT Paclitaxel-Coated Balloon CatheterBoston Scientific Corporation · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.